Hermetica Superfood Encyclopedia
The Short Answer
NattoPharma is a patented menaquinone-7 (MK-7) form of Vitamin K2, derived from fermented natto, that activates carboxylation-dependent proteins including osteocalcin and matrix Gla protein (MGP). These proteins direct calcium into bone tissue while preventing pathological deposition in arterial walls, supporting both skeletal integrity and cardiovascular health.
CategoryBranded Ingredients
GroupOther
Evidence LevelPreliminary
Primary KeywordVitamin K2 MK-7 supplement benefits
NattoPharma (Vitamin K2) — botanical close-up
Health Benefits
Origin & History
Natural habitat
NattoPharma's Vitamin K2 (MenaQ7) is a branded form of menaquinone-7 (MK-7), originally isolated from natto, a fermented soybean product produced by Bacillus subtilis bacteria. It is manufactured via bacterial fermentation followed by extraction in vegetable oil, purification, concentration, and crystallization to yield >95% pure natural MK-7 crystals.
“Natto is a traditional Japanese fermented soybean dish consumed for overall health, with epidemiological observations noting strong bones and low heart disease rates among frequent consumers. No specific duration of use or formalized traditional medicine system is detailed beyond modern dietary consumption.”Traditional Medicine
Scientific Research
The research dossier lacks specific details on clinical trials, RCTs, or meta-analyses for NattoPharma's MenaQ7, with no PubMed PMIDs provided. Evidence primarily consists of epidemiological data from the Rotterdam Study linking K2 intake to cardiovascular benefits and observations of Japanese natto consumption correlating with bone health. NattoPharma has sponsored research validating K2 benefits, but study designs and outcomes are not detailed.
Preparation & Dosage
Traditional preparation
No clinically studied dosage ranges, forms, or standardization details from human trials are specified in the available research. Natural natto contains 900-1200 μg MK-7 per 100g. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
NattoPharma Vitamin K2 is a highly purified menaquinone-7 (MK-7) extract derived from fermented chickpeas (non-soy source), standardized to deliver pharmacologically active doses typically ranging from 45–180 mcg per serving in supplement formulations. The active compound is all-trans MK-7, the biologically superior isomer of Vitamin K2, distinguished from cis-isomers which are considered inactive. As a concentrated micronutrient ingredient, it contains no meaningful macronutrients (protein, fat, carbohydrate), fiber, or caloric value at functional doses. The proprietary form marketed as MenaQ7 is characterized by >97% all-trans MK-7 purity. Bioavailability is significantly superior to Vitamin K1 (phylloquinone) and shorter-chain menaquinones (MK-4): MK-7 has a plasma half-life of approximately 72 hours compared to ~1–2 hours for MK-4, enabling once-daily dosing with sustained tissue saturation. MK-7 is lipid-soluble and requires dietary fat co-ingestion for optimal intestinal absorption via chylomicron-mediated transport. It distributes preferentially to extrahepatic tissues including bone (activating osteocalcin) and arterial walls (activating Matrix Gla Protein). No clinically significant mineral, additional vitamin, or fiber content is present at standard supplement doses.
How It Works
Mechanism of Action
MK-7 serves as a cofactor for gamma-glutamyl carboxylase, the enzyme that carboxylates and thereby activates Vitamin K-dependent proteins. In bone, carboxylated osteocalcin binds hydroxyapatite crystals and facilitates calcium incorporation into the bone matrix. In vasculature, carboxylated matrix Gla protein (MGP) chelates free calcium ions and inhibits BMP-2-mediated vascular smooth muscle cell transdifferentiation, preventing calcification of arterial walls.
Clinical Evidence
A landmark three-year randomized controlled trial (MaasTricht study, n=244 healthy postmenopausal women) found that 180 mcg/day of MK-7 supplementation significantly decreased the progression of age-related arterial stiffness, as measured by pulse wave velocity, compared to placebo. A separate RCT in healthy prepubertal children demonstrated that MK-7 improved carboxylation status of osteocalcin and bone mineral content over 8 weeks. Observational data from the Rotterdam Study (n=4,807) associated higher dietary menaquinone intake with reduced cardiovascular mortality risk, though causality cannot be established from this design. Overall evidence is promising but remains limited by small sample sizes and the need for longer-duration trials specifically using the NattoPharma-branded ingredient.
Safety & Interactions
Vitamin K2 as MK-7 is generally well tolerated, with no established tolerable upper intake level set by major regulatory bodies and no significant adverse effects reported at supplemental doses up to 360 mcg/day in clinical trials. The most clinically significant interaction is with warfarin and other vitamin K antagonist anticoagulants; MK-7 can reduce their anticoagulant efficacy, necessitating medical supervision and INR monitoring. Patients taking antiplatelet agents or other blood-thinning medications should consult a physician before use. Pregnancy safety data are limited, and pregnant or breastfeeding individuals should defer to healthcare provider guidance before supplementing.
Synergy Stack
Hermetica Formulation Heuristic
Frequently Asked Questions
What is the difference between Vitamin K2 MK-4 and MK-7?
MK-4 and MK-7 differ primarily in their side-chain length and resulting pharmacokinetics. MK-7, the form used by NattoPharma, has a geranylgeranyl side chain that confers a serum half-life of approximately 72 hours, allowing once-daily dosing at 90–180 mcg to maintain stable blood levels. MK-4 has a much shorter half-life of roughly 1–2 hours and has typically required much higher doses (1,500–45,000 mcg/day) in clinical studies to show skeletal effects.
How long does it take for Vitamin K2 MK-7 to work for bone health?
Meaningful changes in osteocalcin carboxylation status can be detected within 4–8 weeks of daily MK-7 supplementation at 90–180 mcg. Measurable improvements in bone mineral density and content, however, typically require at least 12–24 months of consistent use, as demonstrated in multi-year clinical trials. Users should not expect rapid structural changes, as bone remodeling is an inherently slow biological process.
Can I take Vitamin K2 with calcium supplements?
Combining Vitamin K2 MK-7 with calcium supplementation is considered a rational strategy, as MK-7 activates the osteocalcin required to direct supplemental calcium toward bone rather than soft tissues. Some researchers argue that calcium supplementation without adequate Vitamin K2 may theoretically increase circulating calcium and vascular calcification risk, though this hypothesis requires further large-scale clinical validation. A common complementary stack includes calcium, Vitamin D3 (which upregulates osteocalcin synthesis), and MK-7 together.
What dose of Vitamin K2 MK-7 is recommended for cardiovascular health?
The MaasTricht RCT, the most cited cardiovascular-focused trial, used a dose of 180 mcg/day of MK-7 and observed significant reductions in arterial stiffness over three years in postmenopausal women. General bone health studies have used 90–180 mcg/day. No universally agreed-upon clinical dosing guideline exists, and doses should be discussed with a healthcare provider, particularly for individuals on anticoagulant therapy.
Does NattoPharma Vitamin K2 interact with warfarin?
Yes, this is the most important drug interaction for Vitamin K2. MK-7 supports the same carboxylation pathways that warfarin inhibits, meaning supplementation can directly counteract warfarin's anticoagulant effect and raise INR toward subtherapeutic levels, increasing clotting risk. Patients on warfarin or any vitamin K antagonist must not begin MK-7 supplementation without physician supervision and regular INR monitoring; in some cases their anticoagulant dose may need adjustment.
Is NattoPharma Vitamin K2 MK-7 suitable for vegans and vegetarians?
NattoPharma Vitamin K2 MK-7 is derived from natto (fermented soybeans), making it suitable for vegetarians and vegans who wish to avoid animal-derived K2 sources like MK-4 from animal products. This plant-based origin is a key differentiator for consumers following plant-forward diets. Always verify the specific product's additional ingredients to ensure full vegan compliance.
What is the bioavailability of NattoPharma Vitamin K2 compared to synthetic K2 supplements?
NattoPharma's naturally-derived MK-7 from natto fermentation demonstrates high bioavailability due to its natural source and longer half-life (approximately 72 hours) compared to synthetic alternatives. The fermentation process enhances K2 concentration and stability, supporting better absorption when taken with fat-containing meals. This natural derivation is associated with more consistent blood levels throughout supplementation.
Who should avoid NattoPharma Vitamin K2 if they have a soy allergy?
Individuals with soy allergies should avoid NattoPharma Vitamin K2 since it is derived from fermented soybeans and may trigger allergic reactions or sensitivities. Those with soy allergies should instead consider alternative K2 sources such as MK-4 from animal products or investigate alternative branded K2 supplements with different base ingredients. Always consult a healthcare provider before substituting supplements if you have known food allergies.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w nattopharma curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
